trial · primary record
Dostarlimab
Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 41 |
| Primary completion | 2028-09-30 |
| Primary endpoint | Durable response rate for 12 months (DRR12) assessed by Blinded independent central review (BICR) |
| Registry ID | NCT06317311 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:16.054Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06317311
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Dostarlimab · compound